---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006084"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:24:00.103709+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M

## Summary
- Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).
- Net loss Q4 $20.3M, FY2022 $65.4M; includes $7.0M loss on debt extinguishment/modification.
- Cash and equivalents $43.1M at Dec 31, 2022; raised $65.7M net from debt/equity in Q4.
- 2023 total revenue guidance $52-55M, representing 36-44% growth over 2022 total revenue.
- Biopharma services revenue $3.7M in FY2022 (-34% YoY); highest dollars under contract entering 2023.

## SEC filing metadata
- accession: 0000950170-23-006084
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/bdsx-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006084
- JSON: https://secwatch.observer/filing/0000950170-23-006084.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006084.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported fourth quarter and fiscal 2022 results: revenue $9.6 million and $38.2 million, net income Net loss of $20.3 million and $65.4 million. Guidance reaffirmed.
  - Period: fourth quarter and fiscal 2022
  - Revenue: $9.6 million and $38.2 million
  - Net income: Net loss of $20.3 million and $65.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue of $9.6 million and $38.2 million for the fourth quarter and fiscal 2022, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm
- Earnings Releases
  BIODESIX INC updated its the fourth quarter and year ended December 31, 2022 guidance (reaffirmed).
  - Period: the fourth quarter and year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: reported results
  source text: On March 6, 2023, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.